Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation
Eleanor Taranto(Unknown), Reid W. Merryman(Harvard University), Oreofe O. Odejide(Dana-Farber Cancer Institute), Robin Joyce(Beth Israel Deaconess Medical Center), Yago Nieto(The University of Texas MD Anderson Cancer Center), Kristin M McHugh(Dana-Farber Cancer Institute), Alex F. Herrera(City of Hope), Yi‐Bin Chen(Massachusetts General Hospital), Caron A. Jacobson(Dana-Farber Cancer Institute), Kimberley-Jane C. Bonjoc(City Of Hope National Medical Center), Parastoo B. Dahi(Memorial Sloan Kettering Cancer Center), Erin Jeter(Dana-Farber Cancer Institute), Philippe Armand(Harvard University), Ammar Chaudhry(City Of Hope National Medical Center), Eric D. Jacobsen(Dana-Farber Cancer Institute), Ann S. LaCasce(Otsuka (Japan)), Jennifer L. Crombie(Dana-Farber Cancer Institute), Austin I. Kim(Dana-Farber Cancer Institute), David C. Fisher(Dana-Farber Cancer Institute), Robert Redd(Harvard University)
Cited by 6
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation
|Blood|2014|880
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
|The Lancet Oncology|2010|852
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
|New England Journal of Medicine|2016|595